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ABSTRACT
Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in 
the Western world. It is becoming increasingly clear that CRC is a diverse disease, 
as exemplified by the identification of subgroups of CRC tumours that are driven 
by distinct biology. Recently, a number of studies have begun to define panels of 
diagnostically relevant markers to align patients into individual subgroups in an 
attempt to give information on prognosis and treatment response. We examined 
the immunohistochemical expression profile of 18 markers, each representing a 
putative role in cancer development, in 493 primary colorectal carcinomas using tissue 
microarrays. Through unsupervised clustering in stage II cancers, we identified two 
cluster groups that are broadly defined by inflammatory or immune-related factors 
(CD3, CD8, COX-2 and FOXP3) and stem-like factors (CD44, LGR5, SOX2, OCT4). The 
expression of the stem-like group markers was associated with a significantly worse 
prognosis compared to cases with lower expression. In addition, patients classified in 
the stem-like subgroup displayed a trend towards a benefit from adjuvant treatment. 
The biologically relevant and poor prognostic stem-like group could also be identified 
in early stage I cancers, suggesting a potential opportunity for the identification of 
aggressive tumors at a very early stage of the disease.
INTRODUCTION
To date, the strongest prognostic value is 
derived from the tumor node metastasis system of 
staging (TNM). Patients with stage I disease have 
the best prognosis, with over 90% surviving past 
five years. These survival rates decrease to less than 
5% for patients with advanced stage IV disease. The 
heterogeneity of colorectal cancers (CRC) at both the 
molecular level and in terms of prognosis is apparent; 
even within each stage, as there exist groups of patients 
with variation in both overall survival and response 
Oncotarget12764www.impactjournals.com/oncotarget
to either standard of targeted treatment strategies. The 
addition of clinicopathological markers such as tumor 
grade, invasion of lymph nodes, blood vessels or 
perineural invasion can further be used to identify poor 
prognostic subgroups of patients within each stage, but 
no definitive molecular signature has yet been attributed 
to these subgroups.
The development of meaningful subgrouping based 
on gene expression data, which related to prognosis, 
was first pioneered in breast cancer by two landmark 
papers in 2000 and 2001 [1, 2]. These paradigm-shifting 
publications emphasized how tumor specific gene 
expression data, through the use of high throughput 
microarray technology, could be used to classify patients 
based on the biology underlying their disease. In the 
last decade a number of studies have been published 
outlining prognostic gene signatures in colorectal cancer 
using various high throughput microarray platforms 
[3–5]. However, as these prognostic signatures were 
purely generated for their prognostic value they failed 
to address the driving biology behind each individual 
cancer or to relate that to potential treatment strategies. 
Given the extreme variation in prognosis, particularly 
in early stage colorectal cancer, these signatures 
were initially aimed at informing clinical decision 
around whether adjuvant treatment following surgery 
would provide any benefit over watchful surveillance. 
Nevertheless, the publication of three recent studies 
sought to set a new paradigm for the classification 
of colorectal cancer based on gene expression profiling 
[6–8]. While each of these studies generated independent 
transcriptional signatures, a common theme was the 
emergence of a stem cell subtype; which defined the 
poor prognostic group in stage II CRC. The importance 
of the prognostic value of this stem cell subtype was 
subsequently validated in the CRC consensus analysis 
presented at the American Society of Clinical Oncology 
(ASCO) meeting in 2014 [9].
Another notable characteristic of these studies 
were that apart from defining the biology driving disease 
progression, they also attempted to develop clinically 
useful IHC panels to assign patients to each subtype. 
To date, these IHC panels have yet to be fully defined 
or validated in retrospective cohorts or prospective 
trial setting. Hence, in this study, we analyze a well-
characterized retrospective CRC cohort in order to test 
the prognostic value of the stem-like and inflammatory 
subtypes, using unsupervised clustering in relation 
to overall survival. This was initially examined in 
stage II cancers, followed by the other cancer stages. 
Moreover, our findings are further tested by patient 
stratification into either in treated and untreated groups, 
with the aim of validating the prognostic value of the 
identified subgroups in CRC using routine standard IHC 
methods.
RESULTS
Unsupervised hierarchical clustering of 
stage II CRC
Consensus unsupervised analysis of the 
immunohistochemistry scoring revealed proteins with 
co-expression patterns that grouped into two distinct 
clusters and one heterogeneous cluster (Figure 1b). 
Expression cluster 1 contained predominately markers 
associated with stem-like characteristics; CD44, LGR5, 
SOX2 and OCT4, while cluster 2 contained inflammatory 
and immune associated markers; CD8, CD3, COX2 
and FOXP3. Cluster 3 was a more heterogeneous group 
containing markers associated with a wider range of 
characteristics. Given the clear biology emerging at this 
stage, we focused on the identified distinct clusters 1 and 2. 
Expression of either a high stem-like or inflammatory 
pattern was not mutually exclusive and resulted in the 
appearance of four clearly distinct patient clusters. Using 
these clusters, we categorized the patients into one of four 
molecular sub-types (MST1–4) based on their expression 
pattern of either the stem-like markers or the inflammatory 
markers. These subtypes were MST1; high stem-like/low 
inflammatory, MST2; high stem-like/high inflammatory, 
MST3; low stem-like/high inflammatory, MST4; low 
stem-like/low inflammatory (Figure 1).
Prognostic relevance of identified molecular 
sub-types in stage II CRC
To investigate the clinical relevance of our identified 
subtypes, we carried out survival analysis using overall 
survival limited to five years in our stage II cohort. While 
there was no significant difference in survival between 
MST1 to 4 (Supplementary Figure S1), there appeared to 
be a trend towards a worse prognosis in MST1 and MST2, 
which both shared high expression of stem-like markers, 
compared to MST3 and MST4. We then re-classified the 
patients into high or low groups for either stem-like or 
inflammatory markers for survival analysis. A significantly 
worse prognosis was found in patients categorized in 
the high stem-like group compared to those with lower 
expression (Supplementary Table S1, p = 0.0288). The 
separation of patients using this stem-like classifier 
(Figure 2b) resulted in a group with a hazard ratio (HR) 
of 2.150 (CI 1.083 – 4.271). In contrast, overall survival 
was unaffected by classification using the inflammatory 
panel of markers.
Effect of adjuvant treatment on prognosis of 
identified subgroups in stage II CRC
Within our stage II cohort, we have patients 
who were either treated with adjuvant chemotherapy 
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(30%) or untreated (70%). Although the treatment 
was heterogeneous, it was predominantly fluorouracil 
based (5FU). Analysis of the patients who received no 
adjuvant treatment confirmed the true prognostic value 
of the stem-like classifier (Figure 2c), with an increased 
HR of 2.345 (CI 1.036 – 5.311; p = 0.0409) in the high-
stem patients compared to the low-stem sub-group. More 
importantly, analysis of the stem-like classifier in the 
treated-only group failed to show any prognostic value to 
the classifier (Supplementary Figure S2), suggesting that 
treatment of patients in the poor prognostic high stem-like 
group might improve their overall survival.
To further test this hypothesis, patients displaying 
a high stem-like classification appeared to show a 
trend towards a benefit from treatment with adjuvant 
chemotherapy as highlighted by an improved overall 
prognosis in the treated group compared to the untreated 
group, although this finding was not significant 
(Supplementary Figure S3).
Identification of stem-like and inflammatory 
associated subgroups in later stage CRC
Following identification of molecular subtypes in 
early stage patients, we carried out a similar unsupervised 
clustering of stage III and stage IV patients in our 
cohort using the same classifiers for both stem-like and 
inflammatory markers (Figure 1c and 1d). This approach 
revealed the presence of all four of our stage II molecular 
subtypes, in each of the later stages, alongside the 
individual stem-like or inflammatory groups. Although 
the presence of both the stem-like and the inflammatory 
Figure 1: Unsupervised hierarchical clustering analysis of immunohistochemical staining profile. Heatmaps showing 
appearance of distinct patients clusters in Stage I a. II b. III c. and IV d. colorectal cancer cases.
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groups could be identified in stage III and IV patients in 
our cohort, there was no prognostic value to our classifier 
in these advanced stage cases.
Prognostic value of the stem-like classifier in  
pre-invasive stage I colorectal patients
Next, we sought to examine whether the stem-
like group, which has prognostic effect in stage II, 
may also identify patients with poor outcome in the 
pre-invasive early disease population. We performed 
survival analysis comparing the stem-high against the 
stem-low group in the stage I cases. As these patients 
have a relatively good prognosis compared to stage II 
patients we used a 10-year follow up for this analysis 
(Figure 2a). We observed a significantly worse overall 
prognosis for patients classified in the stem-high 
group with an increased risk of death over 3 times that 
of the low-stem group (HR = 3.118, CI 1.283 – 7.578, 
p = 0.0121).
Figure 2: Prognostic value of identified stem-like molecular sub-groups in a. Stage I and b. II colorectal cancer 
patients. The prognostic value of the stem-like classifier was also observed in c. Stage II patients who received no adjuvant treatment.
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DISCUSSION
Even though numerous studies have consistently 
showed evidence of different subtypes outlining the 
heterogeneity nature of colorectal cancer [6, 10, 11], 
the integration of these gene expression profiles in the 
clinical context still require extensive validation. Using 
our well-characterized retrospective cohort of patients 
with extensive survival follow-up, we aimed to define 
markers of clinically relevant and diagnostically useful 
subgroups in colorectal cancer. As with a number of 
other studies, we initially focused on the stage II patients 
within our cohort. Using unsupervised consensus-based 
clustering, we found that our dataset subdivided into three 
general clusters based on their IHC profiles (Figure 1, 
Supplementary Tables S2). Although one of these 
clusters represented biology which was heterogeneous in 
nature, it was interesting that the other two clusters were 
underpinned by clearly distinct driving biology, namely, a 
subgroup showing high expression of inflammatory-related 
factors (CD3, CD8, COX-2 and FOXP3) and a subgroup 
showing high expression of stem-like factors (CD44, 
LGR5, SOX2 and OCT4). The identification of these two 
biologically diverse inflammatory-related and stem-like 
clusters have been reported in a number of other studies 
through transcriptional profiling of colorectal cancer [6].
The high expression of the inflammatory-related 
factors CD3, CD8 and FOXP3 has been shown in a 
number of other studies [12–14]. FOXP3 has been 
reviewed to be associated with either good or neutral 
prognostic effect in colorectal cancer [12]. Thus, it has 
been suggested that the favorable prognostic effect of 
FOXP3 may be due to the ability to suppress tumor-
promoting inflammatory responses to gut microbes [13]. 
It has been hypothesized that increased inflammation 
could either provide a favorable environment for the 
dissemination of tumor cells or an indication of protective 
host responses [14]. The improved survival associated 
with CD3 and CD8 expression could be an effect of 
micrometastatic suppression induced by a systemic 
immunosurveillance mechanism [15]. The role of COX2 
in the immune tumor microenvironment in colon cancer 
is well-defined and the uses of inhibitors, such as aspirin, 
in prevention of hereditary cancers of the colon are 
commonly accepted [16, 17].
In normal tissue homeostasis, the regulation of 
cellular renewal is carefully maintained by stem-cells and 
progenitor cells. The loss of this mechanism may be the 
underlying cause of deregulated cell proliferation leading 
to cancer development [18]. Both CD44 and LGR5 are 
widely recognized as key regulators of the stem cell 
phenotype, particularly in colorectal cancer [19, 20]. While 
the transcription factors SOX2 and OCT4 are increasingly 
reported to contribute to cancer progression through their 
functional control of cell self-renewal and the pluripotent 
state [21, 22]. Although both CD133 and p53 appeared to 
cluster within the stem-like subgroup, we chose to leave 
these factors out of further analysis. This was due to the 
overall low levels of staining observed for CD133 within 
our TMA (Table 2) and the current uncertainty about using 
p53 staining as a surrogate for mutation identification. 
Although given the role for both CD133 and p53 in cell 
self-renewal these finding do justify further investigations 
into the relationship of these markers within a stem-like 
signature.
Our finding, which shows that stem-like phenotype 
is associated with worse overall survival in early stage 
colorectal cancer, is very similar to the findings of a 
number of independently published transcriptional based 
classification studies [8–10]. While these other studies 
have proposed IHC markers to define their identified 
subtypes, using our retrospective cohort, we have shown 
that our panel of CD44, LGR5, SOX2 and OCT4 can 
similarly identify this poor prognostic subgroup. We see 
a clear prognostic value of our stem-like classifier in the 
overall stage II population (Figure 2b) and more so in 
the untreated patients, where the true prognostic value 
can be identified (Figure 2c). It is interesting however, 
that when patients in the adjuvant treated group are 
analyzed, the stem-like classifier is no longer prognostic 
(Supplementary Figure S2). Further analysis revealed that 
there was a clear trend for improved survival in the high 
stem-like subgroup following the addition of adjuvant 
treatment, although this effect was not significant, while 
there was no trend for improved survival in the low-stem 
group (Supplementary Figure S3). This trend towards a 
benefit from treatment in the otherwise poor prognostic 
group displays similarities to the study by Sadanandam 
et al., where they found no association between their 
stem-like subtype and DFS in patients receiving adjuvant 
therapy. Similar to the data presented here, when the 
untreated patients were selected individually the stem-like 
group was found to have a significant association with 
lower survival (Figure 2c). Given that a large proportion 
of stage II patients who are given adjuvant therapy do not 
gain any benefit from this treatment, this finding warrants 
further investigation, as current decisions on whether to 
offer adjuvant chemotherapy still rely on a number of 
other classical prognostic factors.
Although stage I patients currently have a very 
favorable outcome, with a 5-year survival rate of over 
90%, we found that the stem-like IHC panel could identify 
a subgroup with a poor overall survival rate (Figure 2a). 
Currently the proportion of patients diagnosed at stage I 
is low, approximately 9% in the UK, but given the recent 
expansion of colorectal cancer screening programs in the 
UK and worldwide, patients identified at this early stage 
will no doubt increase from its current rate [23]. Having 
a routine method of testing the projected increased 
numbers of early stage cases for traits associated with 
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disease progression represents an opportunity for early 
intervention. Evidence for the existence of transcription 
profiles similar to those observed in poor prognostic 
groups of established colorectal cancer have been found in 
early serrated adenoma lesions, with suggestions that the 
driving biology found in the stem-like tumors may already 
be established in precursor lesions [7]. This latter point 
highlights a need for the expansion of similar studies to 
archived polyp collections for further investigation.
In summary, our results clearly reflect the molecular 
heterogeneity of colorectal cancer and are in agreement 
with observations in gene expression profiling studies 
[6, 10, 11]. Our findings also address the relevance of 
inflammatory and stem-like molecular subgroups in 
colorectal cancer. More importantly, the difference in the 
survival outcome between the different subtypes suggest 
that colorectal cancer management could be potentially 
improved by the inclusion of biomarker information 
[24, 25]. In addition the poor-prognostic stem-like 
subgroup identified in this cohort appears to show a 
trend for improved survival rates following adjuvant 
chemotherapy, which may aid in selecting patients who 
will derive benefit from treatment. The results from 
our study may help shed some light on identifying this 
particular subtype for targeted clinical intervention, 
particularly at the very early stage, where there is only 
a small subgroup of patients who will derive any benefit 
from the addition of adjuvant chemotherapy following 
surgery.
MATERIALS AND METHODS
Patient cohort and selection of 
immunohistochemical markers
The patient cohort in this study comprises of 
493 CRC cancer patients that underwent primary surgery 
for the disease from 1990 to 1999 in the National University 
Hospital of Singapore. For this study, formalin-fixed and 
paraffin-embedded tissue blocks were retrospectively 
collected from the Department of Pathology. Clinical 
and pathological data were extracted from the medical 
records for the purpose of the study. The procedure for 
this research was approved by the ethics committee of the 
National University of Singapore. Patient characteristics 
are summarized in Table 1. The information retrieved 
included gender, age, tumor size, tumor stage (AJCC), 
histological grade, vascular invasion, perineural invasion, 
and lymphatic invasion. Patients were staged according 
to the AJCC TNM classification and were monitored for 
relapse of disease and death. Survival time was measured 
from the date of diagnosis until the date of death. Patients 
alive after 60 months was considered censored.
For this study, a panel of 18 immunohistochemical 
markers were analyzed (Table 2). These markers were 
broadly selected and categorized by their putative role 
in development of colorectal cancer such as such having 
tumor suppressive, oncogenic, proliferative, inflammatory 
and stem-like properties.
Tissue microarray construction and 
immunohistochemistry
The details of construction of the tissue microarray 
has been previously described [26]. Briefly, representative 
areas of tumor were initially marked on hematoxylin 
and eosin stained slides by a pathologist. These areas 
were taken from the center of the colorectal tumor and 
were subsequently cored from the donor tissue block 
using a 0.6 mm diameter cylinder. The cylinder cores 
were then transplanted into a recipient paraffin block. 
These processes were carried out using an ATA-100 
tissue arrayer (Chemicon International, Temecula, 
CA, USA). Three cores were taken from tissue blocks 
from each of the patients. A total of 10 tissue microarray 
blocks, arrayed in triplicates, were constructed for this 
study. Consecutive 5-μm sections were then placed 
on polylysine-coated slides for immunohistochemical 
analyses.
Heat-mediated antigen retrieval methods were 
used for all the immunohistochemical markers; these 
were carried out using either the MicroMED TT 
Microwave Processor (Milestone, Sorisole, Italy) 
or the Bond-Max autostainer (Leica Biosystems, 
Newcastle, UK). The immunohistochemistry markers 
used were commercially available and were validated in 
our previous studies (Table 2).
For the antigen-retrieval using the Microwave 
Processor, the sections were subjected to 
steaming at 120°C for 5 min in an antigen retrieval 
solution (10-mM citrate buffer, pH 6.0) (Dako, Glostrup, 
Denmark). To avoid non-specific targeting, they 
were treated with serum-free protein blocking solution 
(Dako, Oslo, Norway) before incubation with the marker 
of interest. The dilution and incubation conditions were 
described in Table 2. After incubation, the slides were 
rinsed twice in saline buffer solution before secondary 
antibody incubation at room temperature for an hour. 
For antibody detection, 3, 30-diaminobenzidine (DAB) 
based detection system (LSAB2; Dako, Norway) was 
used according to manufacturer’s specifications. The 
stained sections were subsequently counterstained with 
haematoxylin.
For markers that were stained using the Bond-Max 
autostainer, the automated immunohistochemical staining 
process was carried out according to the manufacturer’s 
protocol. Briefly, the sections were subjected to heat-
induced antigen retrieval with epitope retrieval ER1 
solution (Leica Biosystems) at 100°C for 20 min. 
Subsequently, they were incubated with the primary 
antibody for 15 min and were washed subsequently with 
Bond washing buffer (Leica Biosystems). After washing, 
Oncotarget12769www.impactjournals.com/oncotarget
the slides were incubated with the secondary antibody 
(Bond Polymer Refine kit, Leica Biosystems) for 8 min 
at room temperature. Finally, chromogenic detection of 
the antibody was achieved by incubation with DAB for 
10 min.
Analysis of immunohistochemistry
Staining results were assessed independently by 
CWO and subsequently reviewed by an experienced 
colorectal pathologist (MST). The scorings were done 
Table 1: Summary of patient characteristics (n = 493)
Clinical parameters Number and percentage of cohort (total n = 493)
Age
< 65 247 (50%)
≥ 65 246 (50%)
Gender
Male 240 (48%)
Female 257 (52%)
AJCC stage
1 and 2 262 (53%)
3 and 4 231 (47%)
Ethnicity
Chinese 429 (87%)
Non-Chinese 68 (13%)
Tumor site
Colon 109 (22%)
Rectal 388 (78%)
Tumor size
< 5 cm 194 (56%)
≥ 5 cm 303 (44%)
Tumor differentiation
Poor 59 (12%)
Well and moderate 438 (88%)
Metastasis status
Positive 121 (25%)
Negative 378 (75%)
Vascular invasion
Present 50 (10%)
Absent 447 (90%)
Perineural invasion
Present 41 (8%)
Absent 456 (92%)
Lymphatic invasion
Present 19 (4%)
Absent 478 (96%)
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Table 2: Summary of characteristics and expression frequency of markers, conditions used for 
immunohistochemistry and previous publications using the same patient cohort
Marker Clone Manufacturer Dilution Expression 
frequency 
(N = 493)*
Localisation Previous 
publication
AXL HPA037422 Sigma Aldrich, MO, USA 1:1000 219 (65%) Cytoplasmic
P Dunne et al., 
Clin Can Res 
(2014) [27]
CD3 LN10 Novocastra, Newcastle, UK 1:1000 246 (50%) Nuclear Unpublished
CD8 11F1 Novocastra, Newcastle, UK 1:40 256 (52%) Nuclear Unpublished
CD133 AC133
Miltenyi 
Biotech, 
CA, USA
1:10 60 (12%) Membrane
CW Ong et al., 
Modern Path 
(2010) [26]
CD44 SFF-304
Bender 
MedSystems, 
CA, USA
1:250 230 (47%) Cytoplasmic Unpublished
CK7 OV-TL-12/30 Santa Cruz, CA, USA 1:500 159 (32%) Cytoplasmic
CW Ong et al., 
Modern Path 
(2010) [26]
CK20 KS20–8 Dako, Denmark 1:500 226 (42%) Cytoplasmic
CW Ong et al., 
Modern Path 
(2010) [26]
COX2 M-19 Santa Cruz, CA, USA 1:250 351 (71%) Cytoplasmic
CW Ong et al., 
Modern Path 
(2010) [26]
FOXP3 236A/E7 Abcam, MA, USA 1:250 234 (47%) Nuclear Unpublished
Ki67 SP6 Abcam, MA, USA 1:200 183 (37%) Nuclear
CW Ong et al., 
Modern Path 
(2010) [26]
LGR5 EPR3065Y
Novus 
Biologicals, 
CO, USA
1:300 245 (70%) Cytoplasmic Unpublished
NHE1 PRS4377 Sigma Aldrich, MO, USA 1:100 335 (68%) Membrane Unpublished
NRCAM ab24344 Abcam, MA, USA 1:500 272 (55%) Cytoplasmic
JY Chan et al., 
Cancer Sci. 
(2011) [28]
OCT4 H-143 Santa Cruz, CA, USA 1:1000 279 (56%) Cytoplasmic
CW Ong et al., 
Modern Path 
(2010) [26]
p27 SX53G8 Abcam, MA, USA 1:500 299 (61%) Nuclear
CW Ong et al., 
Modern Path 
(2010) [26]
(Continued )
Oncotarget12771www.impactjournals.com/oncotarget
blinded to the knowledge of patient outcomes and 
other clinical features. For the markers that expressed 
immunoreactivity in the nucleus (CD3, CD8, FOXP3, 
Ki67, p27 and p53), a pathological score was given 
semi-quantitatively as 0, +1, +2 and +3, corresponding 
to the percentage of positively stained nucleic (Figure 3). 
For the cytoplasmic and membrane expressing markers 
(AXL, CD133, CD44, CK7, CK20, COX2, LGR5, 
NHE-1, NrCAM, OCT4, SOX2 and STMN1), a four-
level semi-quantitative classification corresponding 
to the staining intensity of the cytoplasmic and 
membrane immunoreactivity was used (Figure 3).
Statistical analysis
Only cases with complete information on the 
immunohistochemical markers were considered 
for analysis. Relationships between the occurrence 
frequencies of variables were evaluated by Fisher’s exact 
test. To determine the prognostic value of each variable, 
univariate Cox proportional hazards regression was 
carried out. Subsequently, a multivariate Cox model was 
used to test for independent prognostic value. The data 
were summarized with hazard ratios (HR) with their 95% 
confidence intervals (CI). Survival curves were plotted 
using GraphPad Prism Version 5. The NMF package 
[30] for the R statistical software [31] was used for the 
cluster analysis for the immunohistochemical scores. 
The NMF method allowed identification of clusters in 
an unsupervised manner based on the Euclidean distance 
and average linkage. All other statistical analyses were 
performed using the SPSS package (version 20.0 for Mac, 
SPSS, USA) with significance set at the 5% level.
ACKNOWLEDGMENTS
We would also like to thank Ms Maggie Cheung 
Sok Lian and Ms Sandy Kim Lay Gek for their efforts 
in the collection of patients’ clinical information and 
pathological materials used in this study.
Marker Clone Manufacturer Dilution Expression 
frequency 
(N = 493)*
Localisation Previous 
publication
p53 D-07 Dako, Denmark 1:250 245 (49%) Nuclear
CW Ong et al., 
Modern Path 
(2010) [26]
SOX2 57CT23.3.4 Abcam, MA, USA 1:1000 235 (47%) Cytoplasmic
CW Ong et al., 
Modern Path 
(2010) [26]
STMN1 3352 Cell Signaling, MA, USA 1:250 235 (48%) Cytoplasmic
HT Tan et al., 
J Proteome Res. 
(2012) [29]
*Number of actual cases used in previous studies may differ from the total number of cases examined due to availability 
of clinical information, loss of cores or lack of tumor materials available for pathological scoring purposes during the 
time of study.
Figure 3: Representative immunohistochemistry images for the markers a. CD133, b. SOX2, c. OCT4, d. P27, 
e. P53 and f. COX-2.
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